Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan

International Journal of Urology

Volumn 17, Issue 11, 2010, Pages 905-912

  Okajima, Eijiro ^a,b   Fujimoto, Hiroyuki ^a,c   Mizutani, Yoichi ^a,d   Kikuchi, Eiji ^a,e   Koga, Hirofumi ^a,f   Hinotsu, Shiro ^a,g   Shinohara, Nobuo ^a,h   Miki, Tsuneharu ^a,d  

^a Japanese Urological Association   (Japan)

^b Nara City Hospital   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HARASANSHIN HOSPITAL   (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Etiology; Japan; Neoplasms; Urinary bladder

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CYSTOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING HABIT; SURVIVAL RATE; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CARCINOMA, TRANSITIONAL CELL; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOCIETIES, MEDICAL; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; URINALYSIS; URINARY BLADDER NEOPLASMS; URINE;

EID: 77958592025     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02633.x     Document Type: Article

References (31)

1. Skinner EC. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol. Oncol. 2007; 25: 523-5.
2. Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin. Oncol. 2007; 34: 75-84.
3. Schned AR, Andrew AS, Marsit CJ, Kelsey KT, Zens MS, Karagas MR. Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. Scand. J. Urol. Nephrol. 2008; 42: 237-42.
4. Gardmark T, Bladstroem A, Hellsten S, Maimstroem PU, Members of The Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder cancer in Sweden between 1997 and 2001. Scand. J. Urol. Nephrol. 2006; 40: 276-82.
5. Margel D, Tal R, Goian S, Kedar D, Engeistein D, Baniel J. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 2007; 69: 78-82.
6. Lerner SP, Tangen CM, Scharew M, Wood D, Vrawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high-risk non-muscle invasive tumor. Urol. Oncol. 2009; 27: 155-159.
7. Dalbagni G. The management of superficial bladder cancer. Nat. Clin. Pract. Urol. 2007; 4: 254-60.
8. Lambert EH, Pierorazio PM, Olsson CA et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007; 100: 33-6.
9. Kulhami GS, Finelli A, Fleshner NE et al. Optimal management of high-risk T1G3 bladder cancer: a decision Analysis. PLoS Med. 2007; 4: 1538-49.
10. Okuyama A, Kohri K, Akaza H et al. The report of clinical statistical studies on registered bladder cancer patients in Japan 1999-2001. Nippon Hinyokika Gakkai Zasshi 2006; 97: NP2-31 (in Japanese).
11. Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 2nd edn. Kanehara & Co. Ltd, Tokyo, 1993.
12. Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Kanehara & Co. Ltd, Tokyo, 2001.
13. Sylvester RJ, Van Der Meijden AP, Oosterilimck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 466-75.
14. Denzinger S, Otto W, Fritsche HM et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int. J. Urol. 2007; 14: 995-9.
15. Fernandez-Gomez J, Soisona E, Unda M et al. prognostic factors in patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin: multivariate analysis of data from randomized CUETO trials. Eur. Urol. 2008; 53: 992-1002.
16. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Boehle A, Palou-Redolta J. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. Eur. Urol. 2008; 54: 303-314.
17. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur. Urol. 2008; 53: 146-52.
18. Gupta A, Lotan Y, Bastian PJ et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008; 71: 302-7.
19. Sternberg CN, Calabrò F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-8.
20. Fechner G, Siener R, Reimann M, Kobalz L, Albers P, German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 2006; 60: 27-31.
21. Takahashi T, Higashi S, Nishiyama H et al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J. Clin. Oncol. 2006; 36: 104-8.
22. Andius P, Johansen SL, Holmaeng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70: 758-62.
23. Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki37 and histological grade. Brt J. Cancer 2007; 96: 1711-15.
24. Erdemir F, Ozcan F, Kilicasian I, Pariaktas BS, Uluocak N, Gokce O. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int. Urol. Nephrol. 2007; 39: 1031-7.
25. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Rueter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007; 99: 281-5.
26. Karam JA, Lotain Y, Ashfaq R, Sagalowsky AI, Shariat SF. Surviving expression in patients with non-muscle invasive urothelial cell carcinoma of the bladder. Urology 2007; 70: 482-6.
27. Mhawech-Faucegrlia P, Fischer G, Alyarez Y Jr, Ahmed A, Hermann FR. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int. 2007; 100: 1182-7.
28. Svatek RS, Karam J, Karakiewiccz PI et al. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J. Urol. 2008; 179: 478-84.
29. Kausch I, Doehn C, Jocham D. Recent improvements in the detection and treatment of non-muscle-invasive bladder cancer. Expert Rev. Anticancer Ther. 2006; 6: 1301-11.
30. Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Surger M. Does photodynamic transurethral resection of bladder cancer? A long-term follow-up of a randomized study. BJU Int. 2008; 101: 566-9.
31. Marugame T, Kamo K, Katanoda K et al. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries. Jpn J. Clin. Oncol. 2006; 36: 668-75.